Enzyme-linked Immunosorbent Assay Market Size & Share, by Type (Indirect ELISA, Sandwich ELISA), End User (Hospitals, Pharmaceutical, Research and Academic Institutions) - Global Supply & Demand Analysis & Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5526
  • Published Date: Jan 11, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Enzyme-linked Immunosorbent Assay Market size is anticipated to reach USD 27 Billion by the end of 2036, growing at a CAGR of 6% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of enzyme-linked immunosorbent assay was over USD 12 billion. The escalating prevalence of chronic diseases worldwide stands as a pivotal force driving the robust growth of the market. Chronic diseases, including diabetes, cancer, autoimmune disorders, and infectious diseases, continue to impose a substantial global health burden. ELISA, with its high sensitivity and specificity, plays a pivotal role in the early detection, diagnosis, and monitoring of these conditions, thereby contributing significantly to improved patient outcomes. According to the World Health Organization (WHO), chronic diseases are the leading cause of mortality globally, responsible for approximately 71% of all deaths. Moreover, the global burden of chronic diseases is expected to increase by 57% by 2025. This escalating health crisis underscores the critical need for advanced diagnostic tools like ELISA in effectively managing and combating these ailments.

Enzyme-linked immunosorbent assay is frequently employed in the diagnosis and monitoring of chronic diseases such as diabetes, cancer, infectious diseases, and autoimmune disorders. The increasing prevalence of these conditions globally has driven the demand for diagnostic tools like ELISA. Ongoing technological advancements, such as the development of automated ELISA systems, have enhanced the efficiency and accuracy of the assay. These improvements contribute to the enzyme-linked immunosorbent assay market growth by attracting users seeking more streamlined and high-throughput solutions.


Enzyme-linked Immunosorbent Assay Market Overview
Get more information on this report: Request Free Sample PDF


Enzyme-linked Immunosorbent Assay: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~6%

Base Year Market Size (2023)

~ USD 12 Billion

Forecast Year Market Size (2036)

~ USD 27 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Enzyme-linked Immunosorbent Assay Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Advancements in Technology: The continuous advancements in technology have been a catalyst for the growth of the enzyme-linked immunosorbent assay market. Innovative technologies, such as automated ELISA systems and enhanced detection methods, have significantly improved the accuracy, sensitivity, and efficiency of ELISA assays. Automation, in particular, has streamlined workflows, reduced turnaround times, and minimized the risk of errors, making ELISA an attractive choice for researchers and clinical laboratories seeking high-throughput and reliable diagnostic solutions. As laboratories worldwide transition towards more sophisticated and automated systems, the adoption of technologically advanced ELISA platforms is poised to witness a substantial upswing, driving market growth.
  • Diagnostics and Screening Programs: The World Health Organization (WHO) estimates that around 70% of global deaths are due to non-communicable diseases (NCDs), emphasizing the need for effective diagnostic tools. The emphasis on diagnostics and screening programs as a part of public health initiatives has become a substantial growth driver for the ELISA market. Governments and healthcare organizations worldwide are implementing screening programs for early detection of diseases, especially non-communicable diseases (NCDs) such as diabetes and cardiovascular diseases. ELISA, with its ability to detect specific biomarkers associated with various conditions, plays a pivotal role in these screening programs.
  • Increasing Prevalence of Infectious Diseases: The escalating prevalence of infectious diseases, both globally and regionally, serves as a significant growth driver for the ELISA market. ELISA's sensitivity and specificity make it a crucial tool in the detection of infectious agents, aiding in early diagnosis and effective management. With the continuous emergence of new pathogens and the persistent threat of pandemics, there is an ongoing demand for reliable diagnostic methods to control and mitigate the spread of infectious diseases. ELISA, being a versatile and widely applicable technology, is at the forefront of diagnostics in infectious disease management, driving its increased adoption and market growth.

Challenges

  • Competition from Alternative Technologies: ELISA faces stiff competition from emerging technologies, such as molecular diagnostics (PCR, Next-Generation Sequencing), which offer advantages like higher sensitivity and specificity. This challenge may hinder market growth as laboratories and researchers explore alternative diagnostic methods that might be more suitable for certain applications. Traditional ELISA methods often lack the ability to simultaneously analyze multiple analytes in a single sample, limiting their efficiency in comparison to multiplexing technologies. In scenarios where comprehensive profiling is required, the inability to multiplex may lead researchers to opt for other techniques, potentially affecting the market share of ELISA.
  • Limited Multiplexing Capabilities
  • High Cost of Development


Enzyme-linked Immunosorbent Assay Segmentation

Type (Indirect ELISA, Sandwich ELISA)

The sandwich ELISA segment in the enzyme-linked immunosorbent assay market is estimated to gain the largest revenue share of 62% in the year 2036. Collaborations between academic institutions, biotechnology companies, and pharmaceutical firms foster innovation in biomarker research. Sandwich ELISA, being a cornerstone in this field, benefits from such partnerships. The shared expertise and resources in collaborative projects contribute to the development and validation of sandwich ELISA assays, further propelling its market growth. A study found that strategic collaborations in the life sciences industry have increased by over 30% in recent years. The growth of the sandwich ELISA segment is further driven by the rising demand for cancer biomarkers, advancements in precision medicine, increasing investment in biomarker research, the clinical emphasis on disease monitoring, growing pharmaceutical research activities, and strategic alliances and collaborations in the life sciences industry.

End User (Hospitals, Pharmaceutical, Research and Academic Institutions)

Enzyme-linked immunosorbent assay market from the hospitals segment is expected to garner a significant share in the year 2036. The shift towards personalized medicine involves tailoring medical decisions and interventions based on individual patient characteristics. Hospitals are increasingly adopting personalized approaches to improve treatment efficacy. ELISA's capability to quantify specific biomarkers aligns with the requirements of personalized medicine, enabling hospitals to provide more targeted and effective treatment strategies. The growth of personalized medicine as a paradigm in healthcare contributes to the continued use of ELISA in hospital settings. The global personalized medicine sales are projected to reach USD 3.2 trillion by 2027, according to a report. The hospitals segment's growth in the adoption of ELISA is also driven by the increasing global disease burden, prevalence of infectious diseases, rising cancer incidence, technological advancements in healthcare, the emphasis on early disease detection, and the progression towards personalized medicine.

Our in-depth analysis of the global enzyme-linked immunosorbent assay market includes the following segments:

          Type

  • Indirect ELISA
  • Sandwich ELISA

          End User

  • Hospitals
  • Pharmaceutical
  • Research and Academic Institutions

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Enzyme-linked Immunosorbent Assay Industry - Regional Synopsis

APAC Market Forecast

The enzyme-linked immunosorbent assay market in the Asia Pacific region is projected to hold the largest market share of 40% by the end of 2036. Government initiatives aimed at enhancing healthcare access contribute to the growth of the ELISA market. As healthcare becomes more accessible to a larger population, the demand for diagnostic tools like ELISA increases. Government-backed programs focused on preventive healthcare and disease management create a conducive environment for the adoption of advanced diagnostic technologies, further supporting the growth of the ELISA market. Various countries in the Asia Pacific region have implemented healthcare reforms and initiatives. The Asia Pacific region is witnessing significant advancements in diagnostic technologies, including in vitro diagnostics. As laboratories and healthcare facilities adopt more sophisticated diagnostic tools, ELISA's position as a reliable and widely applicable technology contributes to its increasing adoption. The ongoing technological advancements in the IVD sector drive the growth of the market in the region. The Asia Pacific in vitro diagnostics (IVD) sales are to reach nearly USD 17.22 billion by 2026.

North American Market Statistics

The enzyme-linked immunosorbent assay market in the North America region is projected to hold the second largest share during the forecast period. North America is witnessing a rise in the prevalence of chronic diseases, contributing to increased healthcare expenditures and a focus on early detection. ELISA, known for its accuracy in identifying specific biomarkers associated with chronic conditions, plays a pivotal role in disease diagnosis and management. The demand for advanced diagnostic tools like ELISA is fueled by the imperative to address the growing burden of chronic diseases in the region. According to the Centers for Disease Control and Prevention (CDC), chronic diseases account for 6 in 10 deaths in the United States, with heart disease, cancer, and diabetes being the leading causes. North America is at the forefront of technological advancements in healthcare, and the IVD sector is no exception. The continuous growth of the IVD market underscores the adoption of sophisticated diagnostic tools.

Research Nester
Enzyme-linked Immunosorbent Assay Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Enzyme-linked Immunosorbent Assay Landscape

top-features-companies
    • Thermo Fisher Scientific Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • PerkinElmer, Inc.
    • Bio-Rad Laboratories, Inc.
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd.
    • Siemens Healthineers AG
    • BD (Becton, Dickinson and Company)
    • Agilent Technologies, Inc.
    • BioMérieux SA
    • Ortho Clinical Diagnostics

In-the-news

In The News

  • In July 2023, PerkinElmer acquired Serena Therapeutics, a leader in liquid biopsy technologies for early cancer detection, for USD 2.1 billion. This acquisition significantly expands PerkinElmer's diagnostics portfolio and positions them as a major player in the growing liquid biopsy market.
  • In October 2023, PerkinElmer introduced the EnVista™ 10X microscope, a groundbreaking platform combining high-resolution optical microscopy with powerful correlative analysis capabilities. This innovative tool allows researchers to gain deeper insights into complex biological processes across various disciplines.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5526
  • Published Date: Jan 11, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing demand for healthcare sector is the major factor driving the market growth.

The market size of enzyme-linked immunosorbent assay is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2024-2036.

The major players in the market Thermo Fisher Scientific Inc., PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Merck KGaA (EMD Millipore), F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Enzyme-linked Immunosorbent Assay Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying